Transforming growth factor-b (TGF-b) is the prototypical member of a superfamily of pleiotropic cytokines, which regulate a multitude of biological processes including tissue homoeostasis, angiogenesis, migration and differentiation. TGF-b signals by activation of a heterooligomeric receptor complex consisting of the type II receptor, TGF-b-RII and the type I receptor ALK5. These receptors activate a diverse range of intracellular signal transduction pathways including the canonical Smad pathway. The receptor-associated Smads 2 and 3 (R-Smads), are directly phosphorylated on their carboxy termini by the serine/threonine kinase domain of ALK5. Following phosphorylation the R-Smads heterooligomerise with the co-Smad, Smad4 and accumulate in the nucleus where in conjunction with a number of cofactors they regulate target gene expression.
Transforming growth factor-b (TGF-b) is the prototypical member of a superfamily of pleiotropic cytokines, which regulate a multitude of biological processes including tissue homoeostasis, angiogenesis, migration and differentiation. TGF-b signals by activation of a heterooligomeric receptor complex consisting of the type II receptor, TGF-b-RII and the type I receptor ALK5. These receptors activate a diverse range of intracellular signal transduction pathways including the canonical Smad pathway. The receptor-associated Smads 2 and 3 (R-Smads), are directly phosphorylated on their carboxy termini by the serine/threonine kinase domain of ALK5. Following phosphorylation the R-Smads heterooligomerise with the co-Smad, Smad4 and accumulate in the nucleus where in conjunction with a number of cofactors they regulate target gene expression. 1 TGF-b acts as a potent immunosuppressor by regulating the proliferation and survival of many cells of the immune system. Part of the homoeostatic function of TGF-b is the cell type-specific induction of apoptosis, which occurs in several cell types including B cells. 2 Gene ablation studies in mice have indicated that TGF-b signalling affects B cells at all stages of development and is critical for secreted IgA responses. 3 The observation that many lymphomas (including those derived from germinal centre (GC) B cells undergoing differentiation) have defective TGF-b signalling pathways 4, 5 suggests that disruption of TGF-b apoptotic signalling in human B cells may contribute to lymphomagenesis.
GCs are the main sites for generating high-affinity antibody responses through repeated rounds of selection by apoptotic elimination of unwanted B cells. Activated B cells entering GCs undergo a process where immunoglobulin genes are altered by somatic hypermutation. Overtime, cells carrying mutated receptors with the highest affinity for foreign antigen outcompete others for limiting amounts of antigen and survival signals provided by T-cell help, so ensuring their continued survival and differentiation. 6 At present, cell death at this site is generally thought to occur by Fas-dependent apoptosis (required for deletion of cells carrying low-affinity mutated immunoglobulins 7 ). In addition, B-cell receptor (BCR) ligation in the absence of costimulatory receptor-ligand interactions is important for deletion of autoreactive B cells. In this context, Fas-mediated apoptosis is inhibited by cFLIP L induced by survival signals from CD40 and BCR ligation. In the absence of these signals (e.g. during in vitro culture) cFLIP is rapidly degraded leading to spontaneous apoptosis, 8 a process known as 'death by neglect'. GC B cells are therefore primed to die and require continued environmental cues for survival.
Signalling by CD40 and the BCR may help to render B cells 'Fas-resistant' by induction of the prosurvival BCL-2 homologue, BCL-X L , although there are conflicting reports of its involvement in Fas-mediated cell death. 9 It is likely, however, that BCL-X L or BCL-2 expression induced by survival signals is required to antagonise a mitochondrial 'intrinsic' apoptosis pathway activated by antigen-BCR interaction. BCRmediated cell death correlates with induction of BIM, 10 which is a member of the proapoptotic BCL-2 family of proteins that also includes BIK, NOXA, BAD, BID, BMF and PUMA. These proteins antagonise the function of BCL-2 and its pro-survival homologues (BCL-X L , BCL-w, MCL-1 and A1 11 ) resulting in activation of BAX and BAK. Once activated, BAX and BAK permeabilise the mitochondrial outer membrane 12 to release apoptogenic factors including cytochrome c, which complexes with APAF1 and procaspase-9 to form the apoptosome. Knockout mouse studies have implicated several proapoptotic components of this pathway in B-cell homoeostasis. 10 Previous findings suggest that TGF-b-mediated apoptosis may also be involved in normal human GC B-cell homoeostasis. For example, we and others have shown that some Burkitt's lymphoma (BL) cell lines (which derive from B cells differentiating within GCs) are highly sensitive to TGF-binduced apoptosis. 5, 13, 14 Exogenous TGF-b also enhances apoptosis of primary explanted human and murine B lymphocytes. 3 However, the physiological role of TGF-b signalling in GC reactions, the cell types within this compartment which die in response to TGF-b, and the effector mechanisms TGF-b employs to induce apoptosis remain to be elucidated.
Here we demonstrate that TGF-b contributes to 'death by neglect' by regulating an intrinsic apoptotic pathway in human centroblastic B cells. TGF-b impacts on apoptosis regulators upstream of BAX and BAK, by inducing the proapoptotic BH3-only protein BIK and downregulating BCL-X L . These changes occurred both in BL cell lines and in their normal GC counterparts (centroblasts). Blocking the TGF-b-induced intrinsic pathway in primary human centroblasts provided cells with a survival advantage during spontaneous apoptosis. Our findings identify autocrine TGF-b signalling as a physiological regulator of a default mitochondrial apoptotic pathway in human B cells, and identify a novel function for BIK in B-cell homoeostasis.
Results
Engagement of the intrinsic mitochondrial apoptosis pathway by TGF-b. To determine how TGF-b regulates apoptosis in centroblastic BL cells, we studied the response of a panel of BL cell lines to exogenous TGF-b. Ramos, BL2 and BL40 cells died following TGF-b addition shown by cleavage of the caspase substrate PARP, however, CA46 cells showed no PARP cleavage despite having an intact TGF-b signalling pathway (measured by phosphorylation of Smad2; Figure 1a) .
We next analysed mitochondrial membrane integrity in apoptotic BL cells to determine whether the intrinsic pathway was activated by TGF-b. The gradual loss of the mitochondrial stain tetramethylrhodamine ethyl ester (TMRE) during 48 h treatment of BL cells is consistent with involvement of the intrinsic mitochondrial pathway in TGF-b-induced apoptosis of BL cells (Figure 1b) .
TGF-b regulates multiple BCL-2 family members. Induction of the intrinsic apoptosis pathway requires activation of BAX/ BAK, which in turn is controlled by other members of the BCL-2 family. We therefore screened for transcriptional changes in BCL-2 family members during TGF-b-induced apoptosis. 16, 17 ) was observed ( Figure 2b and Supplementary Figure 2a and b) . BL2 cells lacked BIM expression altogether, but died efficiently upon exposure to TGF-b, indicating that BIM is unlikely to mediate the apoptotic response in the BL cell lines studied. In addition, we observed no change in MCL-1 levels or in BID expression or cleavage to the proapoptotic 15 kDa form, tBid (Supplementary Figure  2b) . TGF-b-mediated apoptosis in BL cells therefore correlated primarily with effects on BIK and BCL-X L .
To address whether these events are critical for apoptosis, we obtained BL cells stably overexpressing BCL-X L . 18 Elevated levels of BCL-X L expression in the stably transfected cells (maintained throughout exposure to TGF-b) reduced the proportion of cells containing active caspase-3 ( Figure 3a ) and reduced cleavage of PARP induced by TGF-b (Figure 3b ). Increased BCL-X L expression therefore largely protected BL cells from TGF-b-mediated apoptosis thus confirming the involvement of mitochondria in the response. To investigate further whether BCL-X L is critical for BL cell survival, we used an inhibitor to block the function of endogenous BCL-X L . BH3i-2 0 inhibits BCL-2 and BCL-X L by binding to their BH3-binding pocket. 19 As BL2, Ramos and BL40 cell lines express BCL-X L but lack BCL-2 protein expression ( Figure 3c ) we used BH3i-2 0 as a selective inhibitor of BCL-X L in BL cells. All three cell lines apoptosed upon treatment with 30 mM BH3i-2 0 . BL2 cells, which express a lower amount of BCL-X L than either Ramos or BL40, were sensitive to 5 mM of the inhibitor (Figure 3d ). Significantly, we were able to sensitise BL cells to TGF-b-induced apoptosis using low dose BCL-X L inhibitor (5 mM; Figure 3e ). Apoptosis induction was greater following combined treatment than was observed with either TGF-b or the BCL-X L inhibitor alone. The synergistic apoptotic response demonstrates that BCL-X L regulation is an important factor in TGF-b-induced apoptosis in BL cells.
To test whether BIK induction is also required for optimal induction of apoptosis, we used a stable shRNA knockdown approach. Nonsilencing control and BIK shRNA retroviral vectors were generated to establish stable Ramos cell lines. qRT-PCR analysis revealed BIK shRNAs reduced expression to below basal levels in comparison with the nonsilencing vector ( Figure 3f ). Importantly, BIK knockdown resulted in a substantial reduction in TGF-b-mediated apoptosis ( Figure 3g ) without affecting TGF-b signalling (data not shown). Taken together, these findings reveal that the levels of BIK and BCL-X L play a critical role in regulating TGF-bdependent apoptosis in centroblastic BL cells. The control of BCL-X L transcription is complex, involving multiple promoters whose activity appears to be cell type and context dependent. 20 As the histone deacetylases (HDACs)-4 and 5 can be involved in repression of promoters by TGF-b, 21 we treated BL cells with an inhibitor of class I and class II HDACs, Trichostatin A (TSA), to gain insight into the possible mechanism of repression of BCL-X L . As expected, TGF-b treatment for 8 h decreased the amount of BCL-X L RNA expressed in both BL2 and BL40 cells. TSA pretreatment of BL cells to inhibit HDAC function, completely blocked the ability of TGF-b to repress BCL-X L transcription (Figure 4c ) without affecting TGF-b signalling (Figure 4d ). In fact, loss of HDAC function switched the response to TGF-b from one of repression to one of activation (in agreement with previous studies of the osteocalcin promoter). 21 TGF-b regulation of BCL-X L transcription may therefore involve chromatin remodelling through the recruitment of repressor complexes containing class I or II HDACs.
Our studies indicate that BIK is an immediate early target of TGF-b signalling in BL cells, and therefore is likely to be (Figure 4f ). Radiolabelled dsDNA probes of SBR1 and SBR2 were prepared (wild-type and mutant SBR2 sequences are shown in Figure 4g ) and used in electrophoretic mobility-shift assays (EMSA) to determine which SBR in the region assayed by ChIP could bind Smad complexes in vitro. SBR2 bound a TGF-b inducible complex which could be supershifted with Smad3 and Smad4 antibodies (Figure 4h ). SBR1 and a mutated form of SBR2, which abrogates the consensus SBEs, were unable to bind Smad3/4 complexes (Figure 4h ). These data suggest that TGF-b activates BIK by direct binding of transcriptionally active Smad3/4 complexes to the SBR2 sequence within the promoter.
Autocrine TGF-b signalling in primary human centroblasts. BLs originate within GCs and phenotypically resemble centroblasts. Exogenously added TGF-b enhances apoptosis of GC B cells in vitro 23 but the mechanism of induction and what contribution TGF-b makes to normal GC development is not fully understood. Having determined how TGF-b induces apoptosis in BL cell lines, we studied whether these responses occur in primary human tonsil cells. In addition to studying the effects of exogenously added TGF-b, we used SB-431542, a selective inhibitor of ALK5, 24 to block endogenous TGF-b signalling. Total mononuclear cells (TMCs), purified CD77 þ ve centroblasts (isolated by positive selection) and TMCs depleted of CD77 þ ve cells responded to exogenous TGF-b as shown by increased Smad2 and Smad3 phosphorylation (Supplementary Figure  3a) . Interestingly, active Smad2 was also detected in untreated cells cultured for 1 h in serum-free medium. This endogenous signalling was completely ablated by treatment with SB-431542 (Supplementary Figure 3a) , which suggests that, in the absence of external sources of cytokine, autocrine TGF-b signalling by the ALK5 receptor occurs in GC B cells and isolated centroblasts. Consistent with this, we found that centroblasts express TGF-b1 mRNA (Supplementary Figure 3b) . Figures 4a and 4b) . Interestingly, when centroblasts were cultured with SB-431542 we were able to consistently prolong cell survival shown by a reduced PARP cleavage (Figure 5c ). In addition, we detected fewer centroblasts containing active caspase-3 following isolation and culture with the ALK5 inhibitor (Figure 5d TGF-b regulates BIK and BCL-X L in primary human centroblasts. To assess whether apoptosis induction is mechanistically similar in both BL cell lines and their normal GC counterparts we analysed whether TGF-b signalling can be detected in intact GCs, and whether BIK and BCL-X L are also TGF-b target genes in primary human centroblasts. Formalin-fixed paraffin-embedded tonsil tissues were stained for phosphorylated Smad2 and Ki67, a marker of proliferation (Figure 6a ). Ki67 highlighted dark and light zones of the GC. Phosphorylated Smad2 was readily detected within both zones as well as in the surrounding mantle zone. A more restricted expression pattern of BIK was detected within the dark and light zones of GCs.
RPA analysis demonstrated that purified CD77 þ ve cells express BCL-X L , and high levels of BIK RNA (Supplementary Figure 5) . BCL-2 was poorly expressed confirming previous observations. 25 Western blotting of lysates from total mononuclear cells (TMCs), purified CD77 þ ve cells and TMCs depleted of centroblasts revealed that whereas BIK protein could only be detected very weakly in TMCs, purified CD77 þ ve cells were strongly positive for BIK, demonstrating that BIK expression is restricted to centroblasts (Figure 6b) . qRT-PCR analysis carried out on purified centroblasts treated with the pancaspase inhibitor ZVAD to inhibit apoptosis showed that BIK and BCL-X L RNA levels were significantly increased and reduced, respectively, by TGF-b addition whereas the levels of BIM were unchanged (Figure 6c ). Taken together, the findings reveal that TGF-b signalling is widespread during GC reactions and that the effectors of apoptotic responses induced by TGF-b in BL cell lines and primary centroblasts are identical.
Discussion
This study reveals that TGF-b mediates apoptosis in GC derived B cells by a mitochondrial intrinsic pathway (Figure 1b) . The mechanism of apoptosis induction involved transcriptional regulation of the BCL-2 family members, BIK and BCL-X L (Figures 2 and 4) . In addition, we provide the first evidence of a causal relationship between BIK and TGF-binduced apoptosis (Figure 3g ) and show that BCL-X L is important for BL cell survival and the outcome of their response to TGF-b signalling. Overall our data indicates that the relative levels of BIK and BCL-X L dictates the apoptotic response of centroblastic cells to TGF-b. We might therefore also predict that cross talk between the TGF-b and BCR receptor signalling pathways is likely, as BIK (as well as BIM) may be regulated by BCR ligation. 26 Upon induction, BH3-only proteins like BIK induce apoptosis by binding directly to prosurvival BCL-2 family members, which constrain BAX and BAK activation. BIK has been described as promoting cell death by sequestering BCL-2 and BCL-X L 27 and antagonising MCL-1 and BCL-X L during apoptosis caused by protein synthesis inhibition. 28 As centroblastic cells express very little BCL-2 (Supplementary Figure 5 ; Klein et al. 25 ) induction of BIK in this cell type is more likely to antagonise the function of BCL-X L and/or MCL-1. Indeed, maintaining BCL-X L protein levels in BL cell lines partially overcame the apoptotic effects of TGF-b (Figure 3a (Figure 3e ). Given the important role of BCL-X L in the TGF-b-mediated apoptotic response, it is possible that the defect in GC apoptosis seen in Bcl-X L transgenic mice, which results in 'relaxed' negative selection and impaired affinity maturation, 29 could be a consequence of a defective default TGF-b apoptosis programme.
BIK is transcriptionally regulated by p53 30 and E2F-1, 31, 32 and we now identify BIK as a novel TGF-b target gene in human B cells via Smad recruitment to the promoter. Our conclusion that BIK is involved in B-cell homoeostasis is supported by the observations that mice with a heritable defect resulting in elevated levels of BIK RNA, have higher levels of apoptosis in splenic B cells, and normal B-cell development can be restored by BCL-X L overexpression. 33 On the other hand, BikÀ/À mice appear quite normal and their B cells are still sensitive to spontaneous apoptosis. 34 To reconcile these observations, it is possible that murine and human B cells respond differently in some respects to TGF-b signalling. Significantly, the SBR recruiting Smads to the endogenous human BIK promoter (shown in Figure 4e and f) is not conserved in the mouse or rat (data not shown), indicating that BIK is unlikely to be involved in TGF-bregulated GC homoeostasis in mice.
Using a selective inhibitor of TGF-b receptor function, we also show that TGF-b signalling through ALK5 is an important physiological modulator of apoptosis of human centroblasts in the absence of survival stimuli ( Figure 5 ). It is possible that exogenous sources of TGF-b may contribute to the regulation of centroblasts in vivo, nevertheless, purified centroblasts exhibited phosphorylation of Smads in the absence of serum and express TGF-b1 RNA (Supplementary Figure 3b) , suggesting that treatment of the cells with SB-431542 inhibits a functional autocrine TGF-b signalling pathway.
Thus far, we have not yet fully elucidated the mechanism of BCL-X L repression. Transcriptional regulation of BCL-X L is complex, involving numerous different transcription factors and three distinct promoters regulating initiation at the 5 0 end of two noncoding exons, IA and IB, and at the beginning of exon II. 20 One possible mechanism of BCL-X L regulation by TGF-b is through increased expression of the TGF-b-induced early genes 1 and 2 (TIEG1 and TIEG2), which regulate BCL-X L levels in oligodendroglial precursor cells. 35 TIEG1 was undetectable in BL cells by western blotting, and whereas TIEG2 was expressed its levels were unaltered by TGF-b (LS, unpublished observations). It therefore seems unlikely that induction of either TIEG1 or 2 is involved in BCL-X L regulation in BL cells. However, our data suggests that (as in the case of TGF-b-mediated repression of osteocalcin) chromatin remodelling in the form of recruitment of HDAC-containing repressor complexes may be involved. Studies are currently underway to characterise the mechanism of repression further.
A model of centroblast death. Overall our data provides evidence for a revised model of centroblast apoptosis (Figure 7 ) to include the novel involvement of TGF-b in regulating an intrinsic apoptosis pathway. We propose that autocrine TGF-b signalling through ALK5 contributes to the default apoptotic state apparent in centroblasts lacking survival stimuli. Parallel Fas (extrinsic) and TGF-b (intrinsic) pathways converge to regulate death by neglect, via caspase-8 and caspase-9, respectively. In line with this, chemical inhibition of caspase-9 activity in explanted GC B cells enhances their survival. 36 Our data implies that survival signals provided during affinity maturation must overcome both pathways.
Our data also suggests that defective TGF-b signalling would provide GC B cells with a survival advantage during selection. Indeed many lymphomas of B-cell origin have aberrant TGF-b signalling or defects in downstream components of the signalling pathway 4 while mutations in BIK have been reported in B-cell lymphomas of GC origin. 37 We hypothesise therefore that disruption of the TGF-b-regulated apoptotic programme in human B cells may contribute to lymphomagenesis and/or autoimmune pathology.
Materials and Methods
Cell lines and reagents. BL cell lines were maintained in RPMI-1640 (Gibco-BRL) supplemented with 5-10% (v/v) heat-inactivated FCS, 2 mM/ml glutamine and antibiotics. Cells were treated as required with 1 ng/ml TGF-b1 (Peprotech), 50 mM zVAD-fmk (Calbiochem) and 10 mM SB-431542 (Tocris). Protein synthesis inhibition was carried out by preincubation for 2 h with 50 mg/ml cycloheximide and 100 mM anisomycin (Sigma). Inhibition of transcription was carried out by pretreatment of cells for 1 h with 2.5 mg/ml actinomycin D (Sigma). The inhibitor of BCL-X L function (BH3i-2 0 ) was purchased from Calbiochem and reconstituted in DMSO at a concentration of 15 mM. For inhibition of HDAC function cells were pretreated for 15 min with 330 nM TSA (Sigma).
Isolation of centroblasts. Ethical permission was obtained for collection and use of normal tonsil tissue (confirmed on histology) from the Southern General Total mononuclear cells (TMCs) were isolated by Ficoll density gradient. CD77 þ ve cells were purified using rat anti-human CD77 (Immunotech) followed by mouse anti-rat IgM (BD Biosciences) and rat anti-mouse IgG1 microbeads (Miltenyi Biotech). Cells were purified using an AutoMacs (Miltenyi Biotech) and were cultured at 371C in RPMI plus 15% FCS at 1 Â 10 7 per ml.
Immunoblotting and antibodies. RIPA lysates were analysed by SDS-PAGE. Antibodies used in western blotting were mouse monoclonals against PARP (BD Biosciences), BIK (FL-160, Santa Cruz), Smad2/3 (BD Biosciences) and actin (Sigma) and rabbit polyclonal antibodies against phospho-Smad 2 (ser465/476), phospho-Smad 3 (ser 433/435), BID and BCL-X L (Cell Signaling), MCL-1 (Santa Cruz) and BIM (Chemicon). Secondary HRP-conjugated antibodies were obtained from Dako. Bound immunocomplexes were detected by enhanced chemiluminescence (Amersham). Prestained protein marker sizes are shown on each gel.
Analysis of cell surface markers by flow cytometry. A total of 1 Â 10 6 cells in PBS/0.5% BSA were labelled on ice for 1 h with the appropriate concentration of antibody before being washed and analysed by FCM (BD FACScan or FacsCalibur). Antibodies used were PE-conjugated anti-CD38 and FITC-conjugated anti-CD77 (BD Biosciences). At least 10 4 events were acquired and analysed using CellQuest software. Analysis gates were set to include 1% of cells of an unstained or isotype matched control stained population.
Analysis of apoptosis by flow cytometry. Cells were fixed, labelled with propidium iodide (PI) and analysed by FCM for sub-2N DNA content, or analysed by measuring intracellular caspase-3 activity using fluorogenic peptide substrates of caspase-3 (PhiPhiLux, G1D2; Calbiochem) as recommended by the manufacturer. To monitor mitochondrial membrane potential, cells were incubated for 20 min in medium containing 40 nM of the mitochondrial stain TMRE (Molecular Probes). Treatment with cyanide-m-chlorophenylhydrazone induced complete mitochondrial membrane depolarisation as a positive control.
RNase protection assay. Total cellular RNA was extracted using Trizol. RPAs were carried out as described previously 38 using the hApo2b multiprobe template set (BD Biosciences Pharmingen).
Retroviral infection of BL cell lines. shRNA-mirs targeting BIK were generated using oligonucleotides described in supplementary text cloned into MSCV/LTRmiR30-PIGDRI (LMP; a kind gift of Ross Dickins and Scott Lowe), 39 Amphotropic retroviruses were generated as described in Supplementary materials and methods. BL cells, seeded at 5000 cells per well in 96-well plates, were infected with viral supernatants by centrifugation at 371C 4000 Â g for 1.5 h. Cells were incubated overnight before addition of growth medium containing 0.6 mg/ml puromycin. Stable cell pools were analysed directly after outgrowth in selection medium.
qRT-PCR. Total cell RNA was isolated using Trizol as recommended by the manufacturer. cDNA and qRT-PCR reactions were prepared using SYBR green 2-step qRT-PCR kits (Finnzymes) and specific primers for each gene (Qiagen). Amplified products were analysed by Chromo4 continuous fluorescence detector and Opticon Monitor3 software. The relative amount of RNA for each gene is expressed after normalisation to the amount of 18S rRNA in each sample.
ChIP assay. CA46 cells (2 Â 10 7 ) were treated with 1 ng/ml TGF-b for 1 h and fixed in 1% formaldehyde for 15 min. Samples were prepared as described in Supplementary text before analysis by PCR.
Immunohistochemistry. Sections (2 mm) of formalin-fixed paraffinembedded human tonsil tissue were stained with antibodies raised against Ki67, BIK or phospho-Smad 2 as described in Supplementary materials and methods.
EMSA. Band shifts were performed as described 40 using the ds oligos described in Supplementary materials and methods. A total of 5 mg of nuclear extract derived from the appropriate cell type and condition was incubated with radiolabelled oligonucleotide probes. For supershifts, anti-Smad3 (Zymed) and anti-Smad4 (Santa Cruz) were also included.
